Proportions of Cells Expressing CD38-/CD34+, CD38+/CD34+, CD19+/CD34+, or CD13,33+/CD34+ in the Regenerating Bone Marrows During Complete Remission of Acute Leukemia or After Bone Marrow Transplantation

Jimin KAHNG; So-Young SHIN; Kyungja HAN.
The Korean Journal of Laboratory Medicine ; : 406-413, 2007.
Artículo en Ko | WPRIM | ID: wpr-161976

Documentos relacionados

  1. CD38 promotes hematopoietic stem cell dormancy.
  2. Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma.
  3. [Proportions of cells expressing CD38-/CD34+, CD38+/CD34+, CD19+/CD34+, or CD13,33+/CD34+ in the regenerating bone marrows during complete remission of acute leukemia or after bone marrow transplantation].
  4. A cytosolic chaperone complex controls folding and degradation of type III CD38.
  5. NAD<sup>+</sup> metabolism drives astrocyte proinflammatory reprogramming in central nervous system autoimmunity.
  6. Mitigation of therapeutic anti-CD38 antibody interference with fab fragments: How well does it perform?
  7. Effect of CD38 on B-cell function and its role in the diagnosis and treatment of B-cell-related diseases.
  8. The CD38 glycohydrolase and the NAD sink: implications for pathological conditions.
  9. Long-Lived Plasma Cells Are Contained within the CD19(-)CD38(hi)CD138(+) Subset in Human Bone Marrow.
  10. Implications of the NADase CD38 in COVID pathophysiology.